Faculty profile

Mark Wainberg

ResearcherLady Davis Institute for Medical ResearchMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Mark Wainberg

Researcher

Lady Davis Institute for Medical Research

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
No publications since 2018.
Principal investigator on 7 research grants (7 CIHR), most recently in 2014.
Supervisor on 7 trainee awards (7 CIHR), most recently in 2015.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Hiv Drug Resistance Allele-Specific Pcr Hiv Transmissibility K65r Mutation Viral Replicative Fitness Viral Transmission Clusters Hiv Primary Infection Hiv Transmission

Latest papers

Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
AIDS research and human retroviruses · 2018
Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
The Journal of infectious diseases · 2017
Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men Receiving Rapid HIV Testing in Montreal, Canada.
AIDS and behavior · 2016 · senior author

All 9 publications

Latest funding

Understanding how HIV integrase inhibitors, integrase inhibitor resistance mutants and non-B DNA reprogram integration site targeting for latency
CIHR · 2016 · Co-investigator
$249,319
The Modulation of R263K-Mediated HIV-1 Resistance to Integrase Strand Transfer Inhibitors by Acetylation.
CIHR · 2015 · Supervisor
$105,000
2nd Afri-Can Forum of CHVI-funded HIV Prevention and Vaccine Teams
CIHR · 2014 · Co-investigator
$10,000

All 31 grants and awards

9 publications.

Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.

Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V, Essex M

AIDS research and human retroviruses2018

DOI: 10.1089/aid.2017.0135 PMID: 29732907

Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.

Godfrey C, Thigpen MC, Crawford KW, Jean-Phillippe P, Pillay D, Persaud D, Kuritzkes DR, Wainberg M, Raizes E, Fitzgibbon J

The Journal of infectious diseases2017

DOI: 10.1093/infdis/jix137 PMID: 28973412

Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men Receiving Rapid HIV Testing in Montreal, Canada.

Otis J, McFadyen A, Haig T, Blais M, Cox J, Brenner B, Rousseau R, Émond G, Roger M, Wainberg M, Spot Study Group

AIDS and behavior2016Senior author

DOI: 10.1007/s10461-016-1344-7 PMID: 26961381

World AIDS Day 2015.

Lever A, Wainberg M

Retrovirology2015Senior author

DOI: 10.1186/s12977-015-0228-7 PMID: 26627883

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M.

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Brenner B, Wainberg M

Journal of the International AIDS Society2014Senior author

DOI: 10.7448/ias.17.4.19738 PMID: 25397483

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc.

Kramer V, Hassounah S, Colby-Germinario S, Mesplède T, Lefebvre E, Wainberg M

Journal of the International AIDS Society2014Senior author

DOI: 10.7448/ias.17.4.19531 PMID: 25394040

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound.

Wainberg M, Anstett K, Mesplede T, Quashie P, Han Y, Oliveira M

Journal of the International AIDS Society2014First author

DOI: 10.7448/ias.17.4.19518 PMID: 25394027

Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic.

Lafeuillade A, Wainberg M, Gougeon ML, Loes SK, Halfon P, Tissot-Dupont H

AIDS research and therapy2014

DOI: 10.1186/1742-6405-11-28 PMID: 25165483

Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.

Papuchon J, Pinson P, Guidicelli GL, Bellecave P, Thomas R, LeBlanc R, Reigadas S, Taupin JL, Baril JG, Routy JP, Wainberg M, Fleury H, Provir/Latitude 45 study group

PloS one2014

DOI: 10.1371/journal.pone.0100452 PMID: 24964202

Understanding how HIV integrase inhibitors, integrase inhibitor resistance mutants and non-B DNA reprogram integration site targeting for latency

Co-investigatorCIHR2016Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research

Principal investigators: Barr, Stephen D

Keywords: Bioinformatics; Hiv Latency; Hiv/Aids; Integrase; Integration Inhibitors; Integration Site Analysis; Molecular Virology; Non-B Dna; Retroviral Integration

$249,319

The Modulation of R263K-Mediated HIV-1 Resistance to Integrase Strand Transfer Inhibitors by Acetylation.

SupervisorCIHR2015Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Anstett, Kaitlin

Keywords: Acetylation; Biochemistry; Dolutegravir; Drug Resistance; Epigenetics; Hiv; Mutagenesis; Selection; Tissue Culture

$105,000

2nd Afri-Can Forum of CHVI-funded HIV Prevention and Vaccine Teams

Co-investigatorCIHR2014Planning and Dissemination Grant - Institute Community Support

Principal investigators: Brockman, Mark A

Keywords: Hiv/Aids

$10,000

What if HIV were unable to develop resistance against a new therapeutic agent?

Nominated PICIHR2014Operating Grant - PA: HIV/AIDS Research Initiative - Biomedical/Clinical Stream

Principal investigators: Wainberg, Mark A

Keywords: Allele-Specific Pcr; Hiv Drug Resistance; Hiv Transmissibility; K65r Mutation; Viral Replicative Fitness; Viral Transmission Clusters

$307,118

Highly stable trimerization of HIV-1 envelope based antigens will improve their immunogenicity and capacity to elicit a neutralizing antibody responses

SupervisorCIHR2013Master's Award: Canada Graduate Scholarships

Principal investigators: Melnychuk, Luca

Keywords: Antibody; Envelope Protein; Hiv-1; Immunology; Trimerization; Vaccinology; Virology

$17,500

Phylogenetic-based prevention interventions to curb the Montreal Men- Having-Sex with Men (MSM) epidemic

Co-investigatorCIHR2013Operating Grant - PA: HIV/AIDS Bridge Funding - Health Services/Pop Hlth Stream

Principal investigators: Brenner, Bluma G

Keywords: Hiv Transmission; Molecular Epidemiology; Phylogenetics; Primary Hiv Infection

CIHR Clinical Trials Network in HIV/AIDS

Co-investigatorCIHR2013CIHR Clinical Trials Network in HIV/AIDS

Principal investigators: Anis, Aslam H; Klein, Marina B; Walmsley, Sharon L

Keywords: Antiretroviral Therapy; Co-Infection; Co-Morbidity; Hcv; Hiv; Immunomodulators; Multicentre Research; Prevention; Randomized Controlled Trials; Vaccines

$22,750,000

Canadian HIV Observational Cohort (CANOC) Collaborative Research Centre

Co-investigatorCIHR2013Centres for HIV/AIDS, Hepatitis C and other STBBIs Research

Principal investigators: Hogg, Robert S; Antoniou, Tony; Bayoumi, Ahmed M; Burchell, Ann N; Cooper, Curtis L; Hull, Mark W; Klein, Marina B; Loutfy, Mona R; Machouf, Nimâ N; Montaner, Julio S; Nosyk, Bohdan P; Raboud, Janet M; Sanche, Stephen E; Tsoukas, Christos M; Wong, Alexander C

Keywords: Aging; Cohort; Collaboration; Comorbidity; Epidemiology; Health Services; Hiv; Policy; Training

$2,726,760

The Canadian HIV Cure Enterprise (CanCURE)

Co-investigatorCIHR2013Team Grant: Canadian Initiative for HIV Cure Research

Principal investigators: Cohen, Eric A; Ancuta, Petronela; Angel, Jonathan B; Estaquier, Jérôme; Fowke, Keith R; Mouland, Andrew J; Ostrowski, Mario A; Routy, Jean-Pierre; Tremblay, Michel J

Keywords: Cd4+ T Lymphocytes And Myeloid Cells; Hiv Cure; Hiv Eradication; Hiv Latency; Hiv Persistence; Human Trials; Humanized Blt Mice Model; Immune-Based Therapies; Non Human Primate Model; Oncolytic Viruses

$8,569,071

Pediatric HIV infection: exploring determinants of a functional cure.

Co-investigatorCIHR2013Team Grant: Canadian Initiative for HIV Cure Research

Principal investigators: Soudeyns, Hugo; Brophy, Jason C; Bitnun, Sean A; Hawkes, Michael T; Kakkar, Fatima; Kaul, Rupert; Lapointe, Normand D; Lavoie, Pascal; Read, Stanley E; Samson, Lindy M; Vaudry, Wendy L

Keywords: Antiretroviral Therapy; Functional Cure; Hiv-Aids; Immunology; Inflammation; Mother-To-Child Transmission; Pathogenesis; Pediatrics; Viral Reservoir; Virology

$1,775,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Mark Wainberg

Research

Latest papers

Latest funding

Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.

Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.

Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men Receiving Rapid HIV Testing in Montreal, Canada.

World AIDS Day 2015.

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M.

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc.

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound.

Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic.

Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.

Understanding how HIV integrase inhibitors, integrase inhibitor resistance mutants and non-B DNA reprogram integration site targeting for latency

The Modulation of R263K-Mediated HIV-1 Resistance to Integrase Strand Transfer Inhibitors by Acetylation.

2nd Afri-Can Forum of CHVI-funded HIV Prevention and Vaccine Teams

What if HIV were unable to develop resistance against a new therapeutic agent?

Highly stable trimerization of HIV-1 envelope based antigens will improve their immunogenicity and capacity to elicit a neutralizing antibody responses

Phylogenetic-based prevention interventions to curb the Montreal Men- Having-Sex with Men (MSM) epidemic

CIHR Clinical Trials Network in HIV/AIDS

Canadian HIV Observational Cohort (CANOC) Collaborative Research Centre

The Canadian HIV Cure Enterprise (CanCURE)

Pediatric HIV infection: exploring determinants of a functional cure.

Frequent collaborators

Bluma Brenner

Joanne Otis

Michel Roger

Martin Blais

Mark Wainberg

Research

Latest papers

Latest funding

Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.

Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.

Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men&#xa0;Receiving Rapid HIV Testing in Montreal, Canada.

World AIDS Day 2015.

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M.

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc.

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound.

Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic.

Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.

Frequent collaborators

Bluma Brenner

Joanne Otis

Michel Roger

Martin Blais

Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men Receiving Rapid HIV Testing in Montreal, Canada.